Company Overview: TGTX

Upcoming Projects (TGTX)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (TGTX)

Don’t see a project related to the company you care about? Create your own!

Expired Projects (TGTX)

Discussing TG Therapeutics’ ublituximab in patients with relapsing forms of multiple sclerosis, following ULTIMATE I & II Phase 3 data reports
Ticker: TGTX
Execute By: Apr 30, 2022
Discussing Ukoniq(umbralisib) in Marginal Zone Lymphoma and Follicular Lymphoma and its future in light of recently announced FDA Investigation into Drug Safety, Risk of Death with Ukonic in UNITY CLL trial
Ticker: TGTX
Execute By: Feb 25, 2022
Discussing TGTX's Umbralisib UNITY-NHL Trial In wake of Rolling NDA Submission in Marginal Zone Lymphoma/Follicular Lymphoma
Tickers: TGTX, BMY, BAYN.XFRA
Execute By: Apr 03, 2020

Upcoming & Overdue Catalysts (TGTX)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (TGTX)

TG Therapeutics (TGTX) withdraws BLA and sNDA for chronic lymphocytic leukemia, pulls Ukoniq from sale
Ticker: TGTX
Occurred on: Apr 15, 2022
TG Therapeutics plans to present top-line overall response rate results from their UNITY-CLL Phase 3 trial in both front line and relapsed or refractory CLL in 2018
Ticker: TGTX
Occurred on: Sep 25, 2018
IPI-549 Combination Dose-Escalation Expected to Complete 2H 2017
Ticker: TGTX
Occurred on: Jan 08, 2018
Interim Data from Phase 2b of UNITY-DLBCL expected 2H 2017
Ticker: TGTX
Occurred on: Aug 10, 2017
UNITY-CLL interim analysis of single agent arms expected 2H 2017
Ticker: TGTX
Occurred on: May 23, 2017
Data from Phase 2 MS trial expected to be presented at a major medical meeting in the first half of 2017
Ticker: TGTX
Occurred on: Apr 28, 2017
Phase 3 top-line data of TG-1101 (Ublituximab) and Imbruvica (GENUINE trial) for Chronic Lymphocytic Leukemia due first half 2017
Ticker: TGTX
Occurred on: Mar 06, 2017
TG Therapeutics, Inc. Announces Publication of Clinical Data from the Phase 1/2 Trial of TG-1101 (ublituximab) Monotherapy in the British Journal of Haematology
Ticker: TGTX
Occurred on: Feb 21, 2017
TG Therapeutics (TGTX) Completes Enrollment for Part 1 of Phase 2 Study of TG-1101 in Relapsing Forms of Multiple Sclerosis (RMS)
Ticker: TGTX
Occurred on: Jan 11, 2017
TG Therapeutics (TGTX) Announces Orphan Drug Designation for the Combination of TG-1101 and TGR-1202 for Treatment of Chronic Lymphocytic Leukemia
Ticker: TGTX
Occurred on: Jan 09, 2017
TG Therapeutics (TGTX) Announces Publication of Clinical Data from the Phase 2 Trial of TG-1101 (ublituximab) in Combination with Ibrutinib in the British Journal of Haematology
Ticker: TGTX
Occurred on: Dec 16, 2016
TG Therapeutics (TGTX) Announces Positive DSMB Recommendation for Continuation of the UNITY-CLL Phase 3 Trial
Ticker: TGTX
Occurred on: Nov 22, 2016
TG Therapeutics (TGTX) Amends the GENUINE Phase 3 Clinical Trial to Accelerate Study Completion by Revising Primary Endpoint to Overall Response Rate
Ticker: TGTX
Occurred on: Oct 13, 2016
Data from a Phase Ib Clinical Trial of TG-1101 in Patients with Neuromyelitis Optica (NMO) presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis
Ticker: TGTX
Occurred on: Sep 16, 2016
TG Therapeutics Announces Orphan Drug Designation for TG-1101 for the Treatment of Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder
Ticker: TGTX
Occurred on: Aug 26, 2016

Strategic Initiatives (TGTX)

TG Therapeutics (TGTX) and Novimmune Announce Global Agreement for Development and Commercialization of a Novel Anti-CD47/ Anti-CD19 Bispecific Antibody
Ticker: TGTX
Announcement Date: Jun 20, 2018

TGTX Overview